Talbot Financial LLC Buys 2,274 Shares of Amgen Inc. (NASDAQ:AMGN)

Talbot Financial LLC boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,791 shares of the medical research company's stock after purchasing an additional 2,274 shares during the period. Talbot Financial LLC's holdings in Amgen were worth $11,153,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the third quarter worth about $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter valued at about $29,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the second quarter valued at about $30,000. Matrix Trust Co bought a new stake in Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen in the third quarter valued at about $56,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Trading Up 3.0 %

NASDAQ AMGN traded up $7.96 during mid-day trading on Monday, reaching $270.19. 3,364,995 shares of the stock were exchanged, compared to its average volume of 3,098,398. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market cap of $145.24 billion, a P/E ratio of 34.60, a P/E/G ratio of 2.91 and a beta of 0.56. The stock has a 50 day simple moving average of $278.16 and a 200-day simple moving average of $308.35. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.96 earnings per share. On average, analysts anticipate that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.52%. Amgen's dividend payout ratio is currently 121.90%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the company a "buy" rating in a report on Monday, October 21st. Dbs Bank raised Amgen to a "strong-buy" rating in a report on Monday, September 16th. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They set a "peer perform" rating for the company. Deutsche Bank Aktiengesellschaft lowered their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Piper Sandler Companies reaffirmed an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.